Endocrine Abstracts

Background: Adrenocortical carcinoma (ACC) is a rare and aggressive endocrine malignancy with poor prognosis and very limited treatment options in advanced disease. The only curative approach is complete surgical resection. Additionally, 60% of patients show endogenous glucocorticoid (GC) excess with clinical apparent hypercortisolism and low to no immune cell infiltration. To date, no therapeutically relevant surface markers are known for ACC, which is why it has not been con...

Background: There is no universally accepted first-line (1L) therapy for higher grade, well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The Phase 3 NETTER-2 study (NCT03972488) evaluated [177 Lu]Lu-DOTA-TATE (hereafter177 Lu-DOTATATE) as 1L treatment in patients with grade (G)2 and G3 advanced GEP-NETs. This is the first trial to assess 1L radioligand therapy (RLT) in any solid tumor.Methods: Eligible pat...

Introduction/Aim: Within the past two decades, the imaging and treatment of patients with neuroendocrine neoplasms (NEN) has been redefined by the successful introduction of radiolabelled somatostatin receptor (SSTR)-agonists targeting SSTR-subtype2 (SSTR2) overexpressed in NEN cells. Reliable assessment of the SSTR status of the primary focus/metastasis in different NEN locations is a cornerstone of NEN management and enables a personalised/precise therapeutic appr...

Background: Bulk genomic studies have identified distinct molecular classes of adrenocortical tumors (ACT). Transcriptome profiles separate benign ACT (“C2” cluster) from carcinomas (ACC) and identify two groups of ACC, “C1A” (“steroid” and “proliferation” signatures) and “C1B” (“immune” signature), of poor and better prognosis respectively. However, these signatures were characterized at the tissue level (“bulk&...

Hepatocellular carcinoma (HCC) is an aggressive tumour frequently associated to an underlying chronic liver disease. In this sense, metabolic dysfunction-associated steatotic liver disease (MASLD) is considered as a growing cause of HCC development. Considering the need of novel therapeutic approaches, and the promising data about targeting the tumour microenvironment in cancer, we performed quantitative proteomics on HCC samples to characterize the components and regulators o...

Atypical parathyroid tumors (APT) represent parathyroid neoplasms characterized by an uncertain malignant potential due to the presence of histological features typical of parathyroid carcinomas (PC), without infiltration of surrounding tissues. The diagnosis of APT can be very challenging. Surgery is often curative but patients with APT may experience recurrence. Although the molecular landscape of benign parathyroid adenoma (PA) and PC has been explored, only few cases of AP...